Table 4.
Patients' outcome and relevant therapies during ICU stay
| COVID‐19 (n = 76) | Non‐COVID‐19 (n = 76) | ||||
|---|---|---|---|---|---|
| Outcome | n | Median (Q3–Q1) or % | n | Median (Q3–Q1) or % | P value |
| Death | 29/76 | 38.2% | 39/76 | 51.3% | 0.142 |
| Discharged from ICU | 47/76 | 61.8% | 37/76 | 48.7% | 0.142 |
| Duration of invasive ventilatory therapy (days) | 63 | 11 (16) | 63 | 10 (12) | 0.124 |
| Duration of ICU stay (days) | 76 | 15 (21) | 76 | 12 (17) | 0.033* |
| Required ICU therapy | |||||
| ECMO | 9/76 | 11.8% | 10/76 | 13.2% | >0.999 |
| Hemofiltration | 22/76 | 28.9% | 28/76 | 36.8% | 0.388 |
| Catecholamines | 59/76 | 77.6% | 68/76 | 89.5% | 0.079 |
| Electrical cardioversion/defibrillation | 6/76 | 7.9% | 14/76 | 18.4% | 0.091 |
| Relevant complications | |||||
| CPR | 6/76 | 7.9% | 10/76 | 13.2% | 0.429 |
| Sustained VT | 3/76 | 3.9% | 2/76 | 2.6% | >0.999 |
| Asystole | 2/76 | 2.6% | 7/76 | 9.2% | 0.167 |
| Pulseless electrical activity | 2/76 | 2.6% | 1/76 | 1.3% | >0.999 |
| Relevant bleeding | 4/76 | 5.3% | 5/76 | 6.6% | >0.999 |
| Thrombosis/thromboembolic event | 18/76 | 23.7% | 4/76 | 5.3% | 0.002* |
| Pulmonary embolism | 13/76 | 17.1% | 2/76 | 2.6% | 0.005* |
| Peripheral thrombosis/thromboembolism | 7/76 | 9.2% | 2/76 | 2.6% | 0.167 |
| Thromboembolic stroke/TIA | 4/76 | 5.3% | 0/76 | 0.0% | 0.120 |
CPR, cardiopulmonary resuscitation; ECMO, extracorporal membrane oxygenation; TIA, transient ischemic attack; VT, ventricular tachycardia defined as VT > 30 s.
Outcome of patients during intensive care unit (ICU) stay.
*
P < 0.05.